All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?

In this video, Jabbour discusses the impact of targeted therapies for adult patients with ALL, including tyrosine kinase inhibitors, monoclonal and conjugated antibodies, bispecific engagers, and chimeric antigen receptor (CAR) T cells. He believes targeted therapies significantly improve the outcomes of patients with high disease burden.

Share: